TrialThe Lancet. Global health2024

Cost-effectiveness of a short-course antibiotic treatment strategy for the treatment of ventilator-associated pneumonia: an economic analysis of the REGARD-VAP trial.

Yiying Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.